

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

THIS PAGE BLANK (USPTO)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) Publication number: **0 622 081 A2**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number: **94302767.2**

(51) Int. Cl.<sup>5</sup>: **A61K 39/09, C07K 13/00,  
C12Q 1/68**

(22) Date of filing: **19.04.94**

(30) Priority: **20.04.93 US 48896**

(43) Date of publication of application:  
**02.11.94 Bulletin 94/44**

(84) Designated Contracting States:  
**AT BE CH DE DK ES FR GB GR IE IT LI LU MC  
NL PT SE**

(71) Applicant: **UAB RESEARCH FOUNDATION  
P.O. Box 1000  
Birmingham Alabama 35294 (US)**

(72) Inventor: **Briles, David E.  
760 Linwood Road  
Birmingham, Alabama 35222 (US)  
Inventor: Yother, Janet L.  
2208 Heatherbrooke Road  
Birmingham, Alabama 35242 (US)  
Inventor: McDaniel, Larry S.  
5354 Cornell Drive  
Birmingham, Alabama 35210 (US)**

(74) Representative: **Smart, Peter John  
W.H. BECK, GREENER & CO  
7 Stone Buildings  
Lincoln's Inn  
London WC2A 3SZ (GB)**

(54) **Epitopic regions of pneumococcal surface protein A.**

(57) A region of the PspA protein of the Rx1 strain of protection-eliciting epitopes which are cross-reactive with PspAs of other *S. pneumoniae* strains. The region comprises the 68 amino acid sequence extending from amino acid residues 192 to 260 of the Rx1 PspA strain.

EP 0 622 081 A2

This invention relates to protein fragments containing epitopic regions of pneumococcal surface protein A (PspA), the major virulence factor of Streptococcus pneumoniae.

Streptococcus pneumoniae is an important cause of otitis media, meningitis, bacteremia and pneumonia. Despite the use of antibiotics and vaccines, the prevalence of pneumococcal infections has declined little over the last twenty-five years.

It is generally accepted that immunity to Streptococcus pneumoniae can be mediated by specific antibodies against the polysaccharide capsule of the pneumococcus. However, neonates and young children fail to make an immune response against polysaccharide antigens and can have repeated infections involving the same capsular serotype.

One approach to immunising infants against a number of encapsulated bacteria is to conjugate the capsular polysaccharide antigens to proteins to make them immunogenic. This approach has been successful, for example, with Haemophilus influenzae b (see U.S. Patent No. 4,496,538 to Gordon and U.S. Patent No. 4,673,574 to Anderson). However, there are over eighty known capsular serotypes of S. pneumoniae of which twenty-three account for most of the disease. For a pneumococcal polysaccharide-protein conjugate to be successful, the capsular types responsible for most pneumococcal infections would have to be made adequately immunogenic. This approach may be difficult, because the twenty-three polysaccharides included in the presently-available vaccine are not all adequately immunogenic, even in adults. Furthermore, such a vaccine would probably be much more expensive to produce than any of the other childhood vaccines in routine use.

An alternative approach for protecting children, and also the elderly, from pneumococcal infection would be to identify protein antigens that could elicit protective immune responses. Such proteins may serve as a vaccine by themselves, may be used in conjunction with successful polysaccharide-protein conjugates, or as carriers for polysaccharides.

In McDaniel et al (I), J. Exp. Med. 160:386-397, 1984, there is described the production of hybridoma antibodies that recognize cell surface proteins on S. pneumoniae and protection of mice from infection with certain strains of encapsulated pneumococci by such antibodies. This surface protein antigen has been termed "pneumococcal surface protein A" or PspA for short.

In McDaniel et al (II), Microbial Pathogenesis 1:519-531, 1986, there are described studies on the characterization of the PspA. From the results of McDaniel (II), McDaniel (III), J. Exp. Med. 165:381-394, 1987, Waltman et al., Microb. Pathog. 8:61-69, 1990 and Crain et al., Infect. Immun. 58: 3293-3299, 1990, it was also apparent that the PspAs of different strains frequently exhibit considerable diversity in terms of their epitopes, and apparent molecular weight.

In McDaniel et al (III), there is disclosed that immunization of X-linked immunodeficient (XID) mice with non-encapsulated pneumococci expressing PspA, but not isogenic pneumococci lacking PspA, protects mice from subsequent fatal infection with pneumococci.

In McDaniel et al (IV), Infect. Immun., 59:222-228, 1991, there is described immunization of mice with a recombinant full length fragment of PspA that is able to elicit protection against pneumococcal strains of capsular types 6A and 3.

In Crain et al, (supra) there is described a rabbit anti-serum that detects PspA in 100% (n = 95) of clinical and laboratory isolates of strains of S. pneumoniae. When reacted with seven monoclonal antibodies to PspA, fifty-seven S. pneumoniae isolates exhibited thirty-one different patterns of reactivity. Accordingly, although a large number of serologically-different PspAs exist, there are extensive cross-reactions between PspAs.

The PspA protein type is independent of capsular type. It would seem that genetic mutation or exchange in the environment has allowed for the development of a large pool of strains which are highly diverse with respect to capsule, PspA, and possibly other molecules with variable structures. Variability of PspA's from different strains also is evident in their molecular weights, which range from 67 to 99 kD. The observed differences are stably inherited and are not the result of protein degradation.

Immunization with a partially purified PspA from a recombinant  $\lambda$ 2 gtlI clone, elicited protection against challenge with several S. pneumoniae strains representing different capsular and PspA types, as described in McDaniel et al (IV), Infect. Immun. 59:222-228, 1991. Although clones expressing PspA were constructed according to that paper, the product was insoluble and isolation from cell fragments following lysis was not possible.

While the protein is variable in structure between different pneumococcal strains, numerous cross-reactions exist between all PspA's, suggesting that sufficient common epitopes may be present to allow a single PspA or at least a small number of PspA's to elicit protection against a large number of S. pneumoniae strains.

In addition to the published literature specifically referred to above, the inventors, in conjunction with co-workers, have published further details concerning PspA's, as follows:

1. Abstracts of 89th Annual Meeting of the American Society for Microbiology, p.125, item D-257, May

1989;

2. Abstracts of 90th Annual Meeting of the American Society for Microbiology, p.98, item D-106, May 1990;

3. Abstracts of 3rd International ASM Conference on Streptococcal Genetics, p.11, item 12, June 1990 ;

4. Talkington et al, Infect. Immun. 59:1285-1289, 1991;

5. Yother et al (I), J. Bacteriol. 174:601-609, 1992;

6. Yother et al (II), J. Bacteriol. 174:610-618, 1992; and

7. McDaniel et al (V), Microbiol Pathogenesis, 13:261-268.

In the co-pending United States patent applications Serial Nos. 656,773 and 835,698 (corresponding to published WO 92/14488) as well as in Yother et al (I) and (II), there are described the preparation of mutants of *S. pneumoniae* that secrete an immunogenic truncated form of the PspA protein, and the isolation and purification of the secreted protein. The truncated form of PspA was found to be immunoprotective and to contain the protective epitopes of PspA. The PspA protein described wherein is soluble in physiologic solution and lacks at least the functional cell membrane anchor region.

In the specification which follows and the drawings accompanying the same, there are utilized certain accepted abbreviations with respect to the amino acids represented thereby. The following Table I identifies whose abbreviations:

TABLE I

AMINO ACID ABBREVIATIONS	
A = Ala = Alanine	M = Met = Methionine
C = Cys - Cysteine	N = Asn = Asparagine
D = Asp = Aspartic Acid	P = Pro = Proline
E = Glu = Glutamic Acid	Q = Gln = Glutamine
F = Phe = Phenylalanine	R = Arg = Arginine
G = Gly = Glycine	S = Ser = Serine
H = His = Histidine	T = Thr = Threonine
I = Ile = Isoleucine	V = Val = Valine
K = Lys = Lysine	W = Try = Tryptophen
L = Leu = Leucine	Y = Tyr = Tyrosine

In accordance with the present invention, there has been identified a 68-amino acid region of PspA from the Rx1 strain of *Streptococcus pneumoniae* which not only contains protection-eliciting epitopes, but also is sufficiently cross-reactive with other PspA's from other *S. pneumoniae* strains so as to be a suitable candidate for the region of PspA to be incorporated into a recombinant PspA vaccine.

The 68-amino acid sequence extends from amino acid residues 192 to 260 of the Rx1 PspA protein. While the disclosure herein refers particularly to the specific 68 amino acid sequence of the Rx1 PspA protein, any region of a PspA protein from any other *S. pneumoniae* species which is homologous to this sequence of the Rx1 PspA protein is included within the scope of the invention, for example, from strains D39 and R36A.

Accordingly, in one aspect, the present invention provides an isolated pneumococcal surface protein A (PspA) protein fragment comprising amino acid residues corresponding to all or some of amino acid residues 192 to 260 of the PspA protein of the Rx1 strain of *Streptococcus pneumoniae* containing at least one protection-eliciting epitope and optionally up to a further 25 residues of said protein in the NH<sub>2</sub> terminal direction and/or the COOH terminal direction, or being effectively homologous with such a protein fragment.

The protein fragment may be one containing an amino acid sequence corresponding to or homologous to the amino acid residues 192 to 260 of the PspA protein of the Rx1 strain and hence may comprise fragments larger or smaller than ones containing the specific amino acid sequence.

The protein fragment of the invention may be produced recombinantly in the form of a truncated C-terminal deleted product containing the protein fragment, specifically a truncated C-terminal-deleted product containing the approximately C-terminal third of an  $\alpha$ -helical region of the native PspA protein.

The amino acid sequence of the protein fragment need not be that found in strain Rx1 but can be based

on a corresponding sequence from another strain. Thus, the present invention also includes an isolated protein fragment comprising an amino acid sequence corresponding to that of a protein-liciting epitope contained in amino acid residues 192 to 260 of the PspA protein of the Rx1 strain of Streptococcus pneumoniae.

In particular, the invention includes an isolated protein fragment comprising the amino acid sequence of or effectively homologous with that of a protection-eliciting epitope corresponding to an epitope contained in amino acid residues 192 to 260 of the pneumococcal surface protein A (PspA) protein of the Rx1 strain of Streptococcus pneumoniae, and including no more than 25 additional amino acid residues in the NH<sub>2</sub> and/or the COOH terminal direction.

The invention includes a vaccine containing a protein fragment of the invention. It also includes certain DNA primers or probes described herein.

The invention will be further described with reference to the following drawings in which:-

Figure 1 contains the DNA sequence for the pspA gene of the Rx1 strain of S. pneumoniae with the deduced amino acid sequence for the PspA protein;

Figure 2 contains a schematic representation of the domains of mature PspA protein as well as identification of certain plasmids containing gene sequences coding for the full length protein (pKSD 1014), coding for specific segments of the N-terminal portion of the protein (pJY4284 or pJY4285, pJY4310, pJY4306) and coding for specific sequences of the C-terminal region of the protein (pBC207, pBC100);

Figure 3 contains a schematic representation of the domains of the mature PspA protein and the general location of epitopes recognised by certain monoclonal antibodies; and

Figure 4 is an immunoblot of PspA protein gene products produced by plasmids identified therein.

As described in the prior U.S. Patent applications referred to above and in Yother et al (I) and (II), the pspA gene of strain Rx1 encodes a 65 kDa molecule composed of 588 amino acids. The nucleotide sequence (SEQ ID No: 1) of the psaA gene and derived amino acid sequence (SEQ ID No: 2) are set forth in Figure 1. The N-terminal half of the molecule is highly charged and its DNA sequence predicts an  $\alpha$ -helical coiled-coil protein structure for this region (288 amino acids), as seen in Figure 2. The C-terminal half of PspA, which is not  $\alpha$ -helical, includes a proline-rich region (83 amino acids) and a repeat region containing the highly conserved twenty amino acid repeats, as well as a slightly hydrophobic sequence of 17 amino acids at the C-terminus. It is known that PspA is anchored to S. pneumoniae by its C-terminal half and it is likely that the proline-rich region serves to tangle the molecule in the cell wall. In addition, it is anticipated that the highly-charged  $\alpha$ -helical region begins at the cell wall and extends into and possibly through the capsule. This model is supported by the observation that the  $\alpha$ -helical domain contains all the surface exposed epitopes recognized by monoclonal antibodies (MABs) reactive with PspA on the pneumococcal surfaces.

The PspA protein of S. pneumoniae strain Rx1 has been mapped to locate protection-eliciting epitopes. Such mapping has been effected by employing antibodies to PspA protein and recombinant fragments of PspA. This mapping technique, described in detail in the Examples below, has identified an amino acid sequence corresponding to the C-terminal third of the  $\alpha$ -helical region of PspA as containing protection-eliciting epitopes, specifically the amino acid residues 192 to 260 of the Rx1 PspA protein. The amino acid sequence from residues 192 to 260 is the C-terminal third of the  $\alpha$ -helical sequence, expected to be near the cell wall surface.

Since the portion of the sequence from residues 192 to 260 contains only 68 amino acids, individual PspA protein fragments of this size may not be optimally antigenic. This difficulty is overcome by producing recombinant proteins containing tandem fragments of different PspAs expressed by gene fusions of the appropriate portions of several pspA genes.

Accordingly, in a further aspect of the invention, there is provided a PspA protein fragment comprising a plurality of conjugated molecules, each molecule comprising amino acid residues 192 to 260 of the PspA protein of the Rx1 strain of Streptococcus pneumoniae and containing at least one protection-eliciting epitope, each molecule being derived from a different strain of S. pneumoniae.

Such tandem molecules can be engineered to maintain proper coiled-coil structure at the points of junction and to be large enough to be immunogenic and to express an array of protection-eliciting epitopes that may cross-react with a wide spectrum of PspAs. Alternatively, individual recombinantly-produced peptides may be attached by chemical means to form a complex molecule.

A further alternative is to attach the PspA fragment to a larger carrier protein or bacterial cell, either as a recombinant fusion product or through chemical attachment, such as by covalent or ionic attachment.

The protein fragments and peptide analogs thereof provided herein are useful components of a vaccine against disease caused by pneumococcal infection. Accordingly, the present invention provides, in a yet further aspect, a vaccine comprising the PspA protein fragments defined herein as an immunologically-active component thereof.

BIOLOGICAL MATERIALS

The Examples which follow as well as in the accompanying drawings, reference is made to certain plasmid materials containing whole or truncated pspA gene sequences. The following Table II provides a summary of such materials:

Table II

Plasmid	Identification	Gene Product
pKSDIO4	whole gene	amino acids 1 to 588
pJY4284 or pJY4285	5' terminal region	amino acids 1 to 115
pJY4310	5'-terminal region	amino acids 1 to 192
pJY4306	5'-terminal region	amino acids 1 to 260
pBC207	3' -terminal region	amino acids 119 to 588
pBCIOO	3' -terminal region	amino acids 192 to 588

EXAMPLESExample 1:

This Example describes the bacterial strains, plasmids and hybridoma antibodies used herein.

*S. pneumoniae* strains, identified in Table III below, were grown in Todd Hewitt broth with 0.5% yeast extract at 37°C or on blood agar plates containing 3% sheep blood in a candle jar. *E. coli* strain DHI (Hanahan, J. Mol. Biol. 166:557) was grown in LB medium or minimal E medium. Plasmids included pUC18 (Gene 33:103), pJY4163 (Yother et al (II)), and pIN-III-ompA (EMBO J. 3:2437).

All antibody-secreting hybridoma lines were obtained by fusions with non-antibody-secreting myeloma cell line P3-X63-Ag.8.653 (J. Immunol. 123:1548). The specific antibodies employed are identified in Table III below. The anti-PspA hybridoma cell lines Xi64, Xi126 and XiR278 have previously been described in McDaniel et al (I) and Crain et al (supra). The remaining cell lines were prepared by immunising CBA/N mice with recombinant D39 PspA expressed in  $\lambda$ gtII by the technique described in McDaniel et al (I). The cell lines producing antibodies to PspA were all identified using an ELISA in which microtitration plates were coated with heat-killed (60°C, 30 mins) *S. pneumoniae* R36A or Rxl, which would select for those MAb that react with surface exposed epitopes on PspA. The heavy chain isotypes of the MABs were determined by developing the ELISA with affinity purified goat antibody specific for  $\mu$  and  $\gamma$  heavy chains of IgM and IgG mouse immunoglobulin. The specificity of the MABs for PspA was confirmed by immunoblot analysis.

All six newly-produced MABs, identified in Table III as XiR 1526, XiR 35, XiR 1224, XiR 16, XiR 1325 and XiR 1323, detected a protein of the expected size (apparent molecular weight of 84 kDa) in an immunoblot of strains Rxl and D39. No reactivity was observed for any of the MABs in an immunoblot of strain WG44.1, a PspA-variant of Rxl (see McDaniel et al (III) and Yother et al (II)).

TABLE III

Reactivities of MAbs with PspAs from <i>Streptococcus pneumoniae</i>												
<i>Streptococcus pneumoniae</i>				Monoclonal Antibody (isotype)								
Strain	Capsule type	PspA type	Ref. #	XIR1526 (IgG2b)	XIR35 (IgG2a)	XIR1224 (IgM)	XI126 (IgG2b)	XiR16 (IgG2a)	Xi164 (IgM)	XIR1325 (IgG2a)	XIR278 (IgG1)	XIR1323 (IgM)
Rx1	rough	25	36	++	++	++	++	++	++	++	++	++
ATCC101813	3	3	37	-	-	-	++	-	++	++	++	++
EF10197	3	18	38	-	-	-	-	-	-	-/+	++	-
RG9739	4	26	38	-	-	-	-	-	-	++	+	++
L81905	4	23	38	-	-	-	-	-	-	-	-	-
BG-5-8A	6A	0	38	-	-	+	-/+	-	-	-	+	+
RG9163	6B	21	38	-	-	-	-	-	-	-	+	-
LM100	22	ND	.	-	-	-	-/+	-	-	-	-	-
WU2	3	1	39	-	-	-	++	-	++	++	++	++
Protection against WU2				-	-	-	+	-	+	+	+	+



Example 2:

This Example describes the provision of the pspA gene from pneumococcal strain Rx1 by polymerase chain reaction (PCR).

PCR primers were designed based on the sequence of the pspA gene from pneumococcal strain Rx1 (see Figure 1). The 5' -primers were LSM3 and LSM4. LSM3 was 28 bases in length and started at base 576 and LSM4 was 31 bases in length and started at base 792, and both contained an additional BamHI site. The 3' pspA primer was LSM2 which was 33 bases in length and started at base 1990 and contained an additional Sall site.

The nucleotide sequences for the primers are as follows

LSM2 5' - GCGCGTCGACGGCTTAAACCCATTACACATTGG-3' (SEQ ID NO:3)

LSM3 5' - CCGGATCCTGAGCCAGAGCAGTTGGCTG-3' (SEQ ID NO:4)

LSM4 5' - CCGGATCCGCTCAAAGAGATTGATGACTCTG-3' (SEQ ID NO:5)

Approximately 10 ng of genomic Rx1 pneumococcal DNA was amplified using a 5' and 3' primer pair. The sample was brought to a total volume of 50 µl containing a final concentration of 50 mM KCl, 10 mM tris-HCl (pH 8.3), 1.5 mM MgCl<sub>2</sub>, 0.001% gelatin, 0.5 mM each primer and 200 mM of each deoxy-nucleoside triphosphate and 2.5 U of Taq DNA polymerase. Following overlaying of the samples with 50 µl of mineral oil, the samples were denatured at 94°C for 2 mins and then subjected to 10 cycles consisting of 1 min. at 94°C, 2 min. at 50°C and 3 min. at 72°C, followed by another 20 cycles of 1 min. at 94°C, 2 min. at 60°C and 3 min. at 72°C. After completion of the 30 cycles, the samples were held at 72°C for an additional 5 min., prior to cooling to 4°C.

Example 3:

This Example describes expression of truncated PspA molecules.

3'-deleted pspAs that express N-terminal fragments in E. coli and which secrete the same fragments from pneumococci were constructed as described in the aforementioned U.S. patent applications Serial Nos. 835,698 and 656,773 (see also Yother et al (II), supra).

For expression of 5'-deleted pspA constructs, the secretion vector pIN-III-ompA was used. Amplified psaA fragments were digested with BamHI and Sall and ligated into the appropriately BamHI/Sall- digested pIN-III-ompA vector, providing the inserted fragment fused to the ompA leader sequence in frame and under control of the lac promoter. Transformants of E. coli DH1 were selected on minimal E medium supplemented with caseamino acids (0.1%), glucose (0.2%) and thiamine (0.05 mM) with 50 µg/ml of ampicillin.

For induction of lac expression, bacteria were grown to an optical density of approximately 0.6 at 660 nm at 37°C in minimal E medium and IPTG was added to a concentration of 2 mM. The cells were incubated for an additional two hours at 37°C, harvested and the periplasmic contents released by osmotic shock. An immunoblot of the truncated PspA proteins produced by the various plasmids is shown in Figure 4.

By these procedures, there were provided, for the 3'-deleted pspAs, plasmids pJY4284, pJY4285, pJY4310 and pJY4306 and for the 5'-deleted pspAs, plasmids pBC207 and PBC100. Plasmid pJY4284 and pJY4285 contain an insert of 564 base pairs, nucleotides 1 to 564 and encoded a predicted 13 kDa PspA C-terminal-deleted product corresponding to amino acids 1 to 115. Plasmid pJY4310 contains an insert of 795 base pairs, nucleotides 1 to 795 and encoded a predicted 21 kDa C-terminal-deleted product corresponding to amino acid 1 to 192. However pJY4306 contained an insert of 999 base pairs, nucleotides 1 to 999 and encoded a predicted 29 kDa C-terminal-deleted product corresponding to amino acids 1 to 260. Plasmid pBC100 contained an insert of 1199 base pairs, nucleotides 792 to 1990, and encoded a predicted 44 kDa PspA N-terminal deleted product containing amino acids 192 to 588. pBC207 contained an insert of 1415 base pairs, nucleotide 576 to 1990, and encoded a predicted 52 kDa PspA N-terminal deleted product containing amino acids 119 to 588.

The pspA gene sequences contained in these plasmids code for and express amino acids as identified in Figure 2.

Example 4:

This Example describes the procedure of effecting immunoassays.

Immunoblot analysis was carried out as described in McDaniel et al (IV). The truncated PspA molecules

prepared as described in Example 3 or pneumococcal preparations enriched for PspA (as described in McDaniel et al (II)) were electrophoresed in a 10% sodium dodecyl sulfate polyacrylamide gel and electro-blotted onto nitrocelluloses. The blots were probed with individual MABs, prepared as described in Example 1.

A direct binding ELISA procedure was used to quantitatively confirm reactivities observed by immunoblotting. In this procedure, osmotic shock preparations were diluted to a total protein concentration of 3 µg/ml in phosphate buffered saline (PBS) and 100 µl was added to wells of Immulon 4 microtitration plates. After blocking with 13 bovine serum albumin in PBS, unfractionated tissue culture supernates of individual MABs were titrated in duplicate by 3-fold serial dilution through 7 wells and developed as described in McDaniel et al (IV) using a goat anti-mouse immunoglobulin alkaline phosphate conjugated secondary antibody and alkaline phosphate substrate. Plates were read in a Dynatech plate reader at 405 nm, and the 30% end point was calculated for each antibody with each preparation.

The protective capacity of the MABs was tested by injecting three CBA/N mice i.p. with 0.1 ml of 1/10 dilution (about 5 to 30 µg) of each hybridoma antibody 1 hr prior to i.v. injection of 10<sup>3</sup> CFU of WU2 or D39 pneumococci (>100 x LD<sub>50</sub>). Protection was judged as the ability to prevent death of all mice in a group. All non-protected mice died of pneumococcal infection within 48 hours post challenge.

#### Example 5:

This Example describes mapping of the epitopes on PspA using the monoclonal antibodies described in Example 1.

The six newly-produced monoclonal antibodies described in Example 1 and identified in Table III were used along with the previously-described monoclonal antibodies Xi64, Xil26 and XiR278 to map epitopes on PspA.

To determine whether each of the MABs recognized different epitopes, each of them was reacted with eight additional *S. pneumoniae* strains, as identified in Table III, in immunoblots of SDS-PAGE separated proteins. Seven different patterns of activity were observed. Three antibodies, XiR16, XiR35 and XiR1526, appeared to recognize epitopes found on Rxl PspA but none of the other PspAs. Accordingly, it was possible that these three antibodies might all react with the same epitope as Rxl PspA.

MAB Xi64 and Xil26 both reacted strongly only with epitopes on ATCC 101813, WU2 and Rxl PspAs, but not with PspAs of the other strains. However, it is known from studies of larger panels of PspAs (as described in McDaniel et al (III) and Crain et al) that Xil26 and Xi64 recognize different determinants.

The remaining four antibodies each exhibited unique patterns of reactivity with the panel of PspAs. Accordingly, the nine antibodies tested recognized at least seven different epitopes on PspA.

For reasons which are not clear, the type 2 strain D39 appeared to be uniquely able to resist the protective effects of antibodies to PspA (McDaniel et al (IV)). As described in McDaniel et al (I), greater than forty times the amount of Xi126 was required to passively protect against the D39 strain as compared to the WU2 strain. None of the six newly-produced monoclonal antibodies protected against the D39 strain. In contrast, immunization of mice with Rxl PspA elicits protection against A66, WU2 and EF6796 strains (mouse virulent pneumococci of capsular types 3, 3 and 6A respectively), all of which have PspA types that are different from those of Rxl and D39 (see McDaniel et al (IV)). In view of the close serologic similarity between the type 25 PspA of Rxl and type 1 PspA of WU2 (Crain et al), WU2 pneumococci were used to challenge mice that had been passively protected with the MABs. All five of the MABs that were observed to bind WU2 PspA were able to protect against infection with 1000 CFU of WU2. Protective antibodies were found in IgM, IgG1, IgG2b and Ig2a heavy chain isotype classes.

#### Example 6:

This Example describes mapping of the epitopes of PspA using the recombinant truncated PspA molecules formed in Example 3.

The five-overlapping C-terminal or N-terminal deleted PspA fragments, prepared as described in Example 3 and shown in Figure 2, were used to map epitopes on PspA. The general location of the epitopes detected by each of the mice MABs, as described in Example 5, was determined using the five C-terminal-deleted and two N-terminal deleted PspA molecules. As a positive control, the reactivity of each antibody was examined with a clone, pKSD1014, expressing full-length PspA.

As noted earlier, the reactivity of the MAB was determined by two methods. In one method, reactivity between the fragments and MAB was evaluated in immunoblots of the fragment preparations after they had been separated by SDS-PAGE. In the second method, a direct ELISA was used to quantify the reactivity of the MABs with non-denatured PspA fragment.

The reactivities observed and the quantification of such activity is set forth in the following Table IV:

Table IV: Reactivity of PspA Fragments with Monoclonal Antibodies<sup>1</sup>

PspA Fragments	Monoclonal Antibodies								
	X1126	X1R35	X1R1526	X1R1224	X1R16	X1R1323	X164	X1R1325	X1R278
pJY4285	++ 72	++ 5	++ <3	++ <3	+	+	+	+	+
pJY4310	++ 116	++ 4	++ <3	++ 5	++ 16	-	+	+	+
pJY4306	++ 1127	++ 78	++ 554	++ 805	++ 2614	++ <3	++ 643	++ 717	++ <3
pBC207	- <3	- <3	- <3	- <3	+	++ 61	++ <3	++ <3	++ 4327
pBC100	- <3	- <3	- <3	- <3	- <3	++ 15	++ 709	++ 4401	++ 4746
Rx1	++ 63	++ 15	++ 42	++ 48	++ 118	++ 44	++ 64	++ 111	++ 468
pIN-III	- <3	- <3	- <3	- <3	- <3	- <3	- <3	- <3	- <3

1. Antibodies were reacted with the indicated PspA fragments in immunoblot of SDS-PAGE separations, or by ELISA using microtitration plates coated with preparations enriched for the indicated

PspA fragments. Rx1 PspA serves as a positive control, and pIN-III-ompA (vector alone) serves as a negative control. The results of the immunoblot are presented as ++ (strong reaction), + (weak but clearly positive reaction) and - (no reaction). ELISA values are given as the reciprocal dilution of each monoclonal antibody that gave 30% of maximum binding with wells coated with the indicated fragment preparation.

The asterisk (\*) after some of the antibodies denotes those which are able to protect against fatal pneumococcal infection with strain WU2 or D39 *S. pneumoniae*.

The deduced locations of the epitopes are indicated in Figure 3.

As can be seen from the data in Table IV, three of the antibodies, Xil26 and XiR35 and XiRI526, react strongly with all three C-terminal-deleted clones in immunoblot analysis, indicating that the sequence required to form the epitope(s) detected by all three lies within the first 115 amino acids of PspA. This map position is in agreement with the failure of these antibodies to react with either of the N-terminal-deleted clones that lack the first 119 and 191 amino acids.

MAB XiRI224 reacted strongly by immunoblot with the longest C-terminal-deleted fragment (pJY4306), but showed substantially weaker reactions with the shorter two C-terminal-deleted fragments. This result indicates that, while the binding site of the antibody may be in the first 115 amino acids, residues beyond amino acid 192 may be important for the conformation or stability of the epitope.

By immunoblot, the three antibodies Xi64, XiRI325 and XiR278, all reacted with the longest C-terminal-deleted fragment and both of the N-terminal-deleted fragments, thus locating their determinants between amino acid positions 192 and 260. Generally confirmatory results were obtained in ELISAs with the native molecules. However, in a few cases, reactions were observed in ELISAs with full length PspA but not with a truncated molecule even though the same truncated fragment was reactive with the antibody by immunoblot. These observations may have resulted from an altered conformation of the truncated fragments under physiologic conditions that masked or prevented the formation of determinant present in full-length PspA and in the denatured fragments.

Two antibodies XiR216 and XiRI323 showed what, at first appeared to be anomalous reactions, indicating that epitopes detected by the antibodies might be in more than one portion of PspA. In view of this unexpected result, the assays were repeated multiple times with two sets of preparations of the truncated fragments. The results of the additional assays confirmed the two-position mapping of epitopes for these two MABs.

By immunoblot, MAB XiR16 reacted strongly with the two longest C-terminal-deleted fragments and failed to react with the shortest N-terminal-deleted fragment. Accordingly, the epitope detected must be N-terminal to position 192. Unexpectedly, MAB XiR16 reacted weakly in immunoblots with both the longest N-terminal-deleted fragment (residues 119 to 158) and the shortest C-terminal-deleted fragment (residues 1 to 115). Since the fragments do not overlap, and if the weak immunoblot reactivities with fragments (reactivities not seen by ELISA) are not an artifact, the MAB XiRI6 must recognize epitopes on both fragments.

In the case of MAB XiRI323, the immunoblot data clearly places the detected epitope between positions 192 and 260. In the ELISA studies, however, XiRI323 reacted strongly and reproducibly with the C-terminal-deleted fragment pJY4310 (amino acid residues 1 to 192) as well as the shortest N-terminal-deleted fragment pBC100 (amino acid residues 192 to 588). Curiously, an ELISA reaction was not observed between MAB XiRI323 and pJY4306 (amino acid residues 1 to 260), even though MAB XiRI323 reacted strongly with this fragment by immunoblot.

These findings provide additional evidence for distal conformation effects on antigenic determinants of PspA. They also indicate that, on the native fragments, MAB XiRI323 sees epitopes on both sides of position 192. The relationship between expression of the epitopes in other PspAs and their position in Rxl PspA is demonstrated in Table IV in which is listed the antibodies in accordance with their apparent map position in PspA. The five antibodies (including XiRI6) that clearly recognize epitopes N-terminal to position 116 are listed at the left side of Table IV. The four antibodies that clearly recognize epitopes C-terminal to position 192 are listed on the right side of Table IV. Three of the five epitopes N-terminal of position 192 (those recognized by XiRI526, XiR35, and XiR16) were not found on any of the other eight PspAs tested. One epitope (recognized by XiR1224) was weakly expressed by one other strain and another (recognized by Xil26) was expressed on two other strains. In contrast, the four epitopes present in the C-terminal third of the PspA  $\alpha$ -helical region were each present in from two to six other strains. The greater conservation of the region C-terminal to position 192, as compared to the region N-terminal to position 192 was significant at  $P < 0.05$  by both the Chi-square and the two sample rank tests. Based on the mapping results (Table III) and the strain distribution results (Table IV), it is apparent that all of the antibodies except possibly XiR35 and XiRI526 must recognize different PspA determinants.

#### Example 7:

This Example contains a discussion of the mapping results achieved in Example 6.

The results set forth in Example 6 clearly demonstrate that the protection eliciting epitopes of PspA are not restricted to the N-terminal end of the surface exposed  $\alpha$ -helical half of the molecule. In fact, four of the five antibodies protective against *S. pneumoniae* WU2 reacted with the C-terminal third of the  $\alpha$ -helical region of PspA. This portion of the  $\alpha$ -helical region is thought to be closest to the cell wall (see Yother et al (II)).

About half of the MABs recognized determinants N-terminal to amino acid 115 and the other half recognized

epitopes C-terminal to residue 192. Since the nine antibodies were selected for their ability to bind native PspA on the surface of heat-killed whole pneumococci, the distribution of the epitopes they recognize suggests that determinants between positions 115 and 192 are either not immunogenic or are not exposed on the native molecule as expressed on pneumococci.

Curiously two MAbs (XiRI6 and XiRI323) appeared to possibly react with epitopes in more than one position on PspA. Although the bulk of the data for XiRI6 placed its epitope N-terminal of position 115, weak immunoblot patterns suggested that a reactive epitope(s) may also exist C-terminal to residue 115. In the case of XiRI323, the bulk of the data indicated that its epitope is between positions 192 and 260. However, the ELISA assay showed significant reactivity of the antibody with a C-terminal-deleted PspA fragment extending from residues 1 to 192. Although there are no extensive repeats in the N-terminal half of PspA, there are a few short repeated sequences that occur more than once in the coiled-coil motif. One such sequence is glu-glu-ala-lys which starts at amino acid positions 105, 133, and 147 and another is lys-ala-lys-leu starting at positions 150 and 220 (see Figure 1). In the case of XiRI323, the antibody reacted with the epitope on the 1 to 192 fragment under native but not denatured conditions. This may indicate that the epitope is conformational and may not have the same exact sequence as the epitope recognized (under both native and denatured conditions) between residues 192 and 260.

One mechanism that may account for the lack of exposure of epitopes between amino acid 115 and 192 would be a folding back of this portion of the  $\alpha$ -helical sequence on itself or other parts of PspA to form a coiled-coil structure more complex than a simple coiled-coil dimer. If this occurred, it could explain how PspA tertiary structure can sometimes be dependent on distant PspA structures. A suggestion that this might, in fact, be the case comes from the observation that some of the truncated forms did not express certain epitopes under physiologic conditions that were detected on the whole molecule under the same conditions and were shown to be present in the fragment after denaturation in SDS.

Since a PspA vaccine may need to contain fragments of several serologically different PspAs, it would be desirable to include in a vaccine only those portions of each PspA that are most likely to elicit cross-protective antibodies. Based on the results presented herein with Rxl PspA, it appears likely that the portion of the PspA sequences corresponding to residues 192 to 260 of Rxl PspA is the best portion of PspA to include in a recombinant PspA vaccine. The epitopes in this portion of PspA were three and a half times as likely to be present in the PspAs of other strains as the epitopes in the residue 1 to 115 portion of the sequence, and none of the 9 antibodies studied clearly reacted with the middle third of the  $\alpha$ -helical region.

#### Example 8:

This Example shows protection of mice by PspA fragments. Five mice were immunized with purified fragment produced by pBC207 in *E. coli* and five with purified fragment produced by pBC100 in *E. coli*. In both cases, the fragments were injected in Freund's complete adjuvant. All mice immunized with each fragment survived challenge with 100 x LD<sub>50</sub> of WU2 capsular type 3 *S. pneumoniae*.

Five additional mice were injected with adjuvant plus an equivalent preparation of non-PspA producing *E. coli*. All mice died when challenged with the same dose of WU2.

The data presented in this Example conclusively proves that epitopes C-terminal to amino acids 119 and 192 respectively are capable of eliciting protective immunity. This result is consistent with the findings presented in the earlier Examples that the region of PspA from amino acids 192 to 260 contain protection-eliciting epitopes.

#### SEQUENCE IDENTIFICATIONS

- SEQ ID NO: 1 DNA sequence for pspA gene (Figure 1)
- SEQ ID NO: 2 Deduced amino acid sequence for PspA protein (Figure 1)
- SEQ ID NO: 3 Nucleotide sequence for PCR primer LSM 2
- SEQ ID NO: 4 Nucleotide sequence for PCR primer LSM 3
- SEQ ID NO: 5 Nucleotide sequence for PCR primer LSM 4

In summary of this disclosure, the present invention provides a PspA protein fragment which contains protection-eliciting epitopes and which is cross-reactive and can be incorporated into a vaccine against disease caused by pneumococcal infection. Modifications are possible within the scope of this invention.

The term "effectively homologous" used herein means in relation to an amino acid sequence effectively homologous to a defined sequence, that the said amino acid sequence may not be identical to said defined sequence but may be at least 70 percent, more preferably 80 percent, still more preferably 90 percent identical, provided that the antigenic epitope or epitopes in said amino acid sequence have properties substantially the same as the corresponding epitopes in said defined sequence.

Now that the region constituted by residues 192 to 260 in the PspA protein of the Rx1 strain has been identified, those skilled in the art will readily be able to produce by recombinant techniques protein fragments according to the invention. In particular, they may tailor DNA probes to use in a PCR reaction to amplifying genomic DNA coding for a desired fragment, insert the amplified DNA into a suitable plasmid vector and utilise the vector in a known manner to express the protein in a suitable host such as *E. coli*, adapting the methods taught in Example 3 above.

It will be possible to clone and express the appropriate pspA fragments and express their truncated products under the control of an appropriate promoter, e.g. a vector containing the *E. coli* lac promoter expressing the *E. coli* ompA and leader sequence to create an ompA::pspA fusion plasmid. Optionally, the sequence coding for the PspA fragment may be linked to a sequence coding for a further protein suitable for injection into humans. Such proteins would likely be those already used as vaccines because they are known to elicit protective immune responses and/or known to function as strong immunologic carriers. Such proteins could include the partial or complete amino acid sequence of toxins such as tetanus toxin, or outer membrane proteins such as that of group B subtype 2 *Neisseria meningitidis*.

It will also be possible to produce a fusion protein composed of the cross-reactive protection-eliciting regions of several different PspA molecules. Such a fusion protein could be made large enough ( $\geq 40,000$  molecular weight) to be highly immunogenic and as a single protein could elicit cross-protection to as many different pneumococci as possible. The combination of cross-protective 70 amino acid regions from 5 to 6 PspAs would be large enough to be highly immunogenic. Constructs expressing epitopes from more than one PspA are especially attractive since PspAs of pneumococci are known to differ serologically. Present evidence indicates that a widely protective vaccine will need to contain cross-reactive protection-eliciting epitopes from more than one different pneumococcus.

It is possible to design such a fusion protein so that it also carries a domain that would help with isolation by including the choline binding region of PspA, or a ligand binding domain from other proteins (such as the maltose binding protein [encoded by malE] of *E. coli*). In the former case the fusion protein could be isolated by adsorption to a choline Sepharose column and elution using 2% choline chloride. In the latter case adsorption would be to a mannose-Sepharose column followed by elution with a solution containing mannose.

In the construction of such a fusion protein containing tandem cross-reactive coiled-coil PspA regions it will be critical not only that the appropriate open reading frame of each downstream gene fragment be preserved at the junctions of the ligated gene fragments, but that the heptad motif of the coiled-coil amino acid sequence not be disrupted. One way to accomplish the latter would be to construct the gene fusions so that they occur within naturally occurring noncoil-coiled regions found in the  $\alpha$ -helical domain of PspA. In our previous report (Yother and Briles J. Bact. T/4:601-609) such non-coiled-coil breaks were identified at amino acid positions 169-176, 199, 225, 254, 274 and 289. Fusions between two or more cross-protective regions (residues 192-260) at or near positions 170 or 199 at one end and at or near residues 274 or 289 at the other end, would be expected to very likely be able to express the epitopes normally expressed within the coiled-coil regions.

In each case, the easiest way to prepare such constructs would be by PCR amplification of the DNA used to construct the gene fusions. In this way it will be possible to prepare the relevant sequence with appropriate restriction sites. The design of gene fusions and the PCR primers used to produce the individual pspA fragments will be carried out so that the proper reading frame will be preserved in each fused gene fragment at the nucleotide level.

It is also possible to synthesise peptides according to the invention having the appropriate amino acid sequence by conventional peptide synthesis.

SEQUENCE LISTINGS

## (1) INFORMATION FOR SEQ ID NO:1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2085 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: double  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (iii) HYPOTHETICAL: NO

## (iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Streptococcus pneumoniae  
 (B) STRAIN: Rx1

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: JY4313

## (ix) FEATURE:

- (A) NAME/KEY: intron  
 (B) LOCATION: 1..2085

## (ix) FEATURE:

- (A) NAME/KEY: CDS  
 (B) LOCATION: join(127..1984)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

30	AAGCTTATGA TATAGAAATT TGTAACAAAA ATGTAATATA AAACACTTGA CAAATATTTA	60
	CGGAGGAGGC TTATACTTAA TATAAGTATA GTCTGAAAAT GACTATCAGA AAAGAGGTAA	120
	ATTTAG ATG AAT AAG AAA AAA ATG ATT TTA ACA AGT CTA GCC AGC GTC	168
	Met Asn Lys Lys Lys Met Ile Leu Thr Ser Leu Ala Ser Val	
	1 5 10	
35	CCT ATC TTA GGG GCT GGT TTT GTT GCG TCT CAG CCT ACT GTT GTA AGA	216
	Ala Ile Leu Gly Ala Gly Phe Val Ala Ser Gln Pro Thr Val Val Arg	
	15 20 25 30	
40	GCA GAA GAA TCT CCC GTA GCC AGT CAG TCT AAA GCT GAG AAA GAC TAT	264
	Ala Glu Glu Ser Pro Val Ala Ser Gln Ser Lys Ala Glu Lys Asp Tyr	
	35 40 45	
	GAT GCA GCG AAG AAA GAT GCT AAG AAT GCG AAA AAA GCA GTA GAA GAT	312
	Asp Ala Ala Lys Lys Asp Ala Lys Asn Ala Lys Lys Ala Val Glu Asp	
	50 55 60	
45	GCT CAA AAG GCT TTA GAT GAT GCA AAA GCT GCT CAG AAA AAA TAT GAC	360
	Ala Gln Lys Ala Leu Asp Asp Ala Lys Ala Ala Gln Lys Lys Tyr Asp	
	65 70 75	
50	GAG GAT CAG AAG AAA ACT GAG GAG AAA GCC GCG CTA GAA AAA GCA GCG	408
	Glu Asp Gln Lys Lys Thr Glu Lys Ala Ala Leu Glu Lys Ala Ala	
	80 85 90	

EP 0 622 081 A2

5	TCT Ser 95	GAA Glu	GAG Glu	ATG Met	GAT Asp	AAG Lys 100	GCA Ala	GTG Val	GCA Ala	GCA Ala 105	GTT Val 105	CAA Gln	CAA Gln	GCG Ala	TAT Tyr	CTA Leu 110	456
	GCC Ala	TAT Tyr	CAA Gln	CAA Gln	GCT Ala 115	ACA Thr	GAC Asp	AAA Lys	GCC Ala 120	GCA Ala	AAA Lys	GAC Asp	GCA Ala	GCA Ala	GAT Asp 125	AAG Lys	504
10	ATG Met	ATA Ile	GAT Asp	GAA Glu 130	GCT Ala	AAG Lys	AAA Lys	CGC Arg	GAA Glu 135	GAA Glu	GAG Glu	GCA Ala	AAA Lys	ACT Thr 140	AAA Lys	TTT Phe	552
	AAT Asn	ACT Thr	GTT Val 145	CGA Arg	GCA Ala	ATG Met	GTA Val	GTT Val 150	CCT Pro	GAG Glu	CCA Pro	GAG Glu	CAG Gln 155	TTG Leu	GCT Ala	GAG Glu	600
15	ACT Thr 160	AAG Lys	AAA Lys	AAA Lys	TCA Ser	GAA Glu 165	GAA Glu	GCT Ala	AAA Lys	CAA Gln	AAA Lys	GCA Ala 170	CCA Pro	GAA Glu	CTT Leu	ACT Thr	648
20	AAA Lys 175	AAA Lys	CTA Leu	GAA Glu	GAA Glu 180	GCT Ala 180	AAA Lys	GCA Ala	AAA Lys	TTA Leu	GAA Glu 185	GAG Glu	GCT Ala	GAG Glu	AAA Lys	AAA Lys 190	696
	GCT Ala	ACT Thr	GAA Glu	GCC Ala	AAA Lys 195	CAA Gln	AAA Lys	GTG Val	GAT Asp 200	GCT Ala	GAA Glu	GAA Glu	GTC Val	GCT Ala	CCT Pro 205	CAA Gln	744
25	GCT Ala	AAA Lys	ATC Ile	GCT Ala 210	GAA Glu	TTG Leu	GAA Glu	AAT Asn	CAA Gln 215	GTT Val	CAT His	AGA Arg	CTA Leu	GAA Glu 220	CAA Gln	GAG Glu	792
	CTC Leu	AAA Lys	GAG Glu 225	ATT Ile	GAT Asp	GAG Glu	TCT Ser	GAA Glu 230	TCA Ser	GAA Glu	GAT Asp	TAT Tyr	GCT Ala 235	AAA Lys	GAA Glu	GGT Gly	840
30	TTC Phe 240	CGT Arg	GCT Ala	CCT Pro	CTT Leu	CAA Gln	TCT Ser	AAA Lys 245	TTG Leu	GAT Asp	GCC Ala	AAA Lys 250	AAA Lys	GCT Ala	AAA Lys	CTA Leu	888
35	TCA Ser 255	AAA Lys	CTT Leu	GAA Glu	GAG Glu	TTA Leu 260	AGT Ser	GAT Asp	AAG Lys	ATT Ile 265	GAT Asp	GAG Glu	TTA Leu	GAC Asp	GCT Ala 270	GAA Glu	936
	ATT Ile	GCA Ala	AAA Lys	CTT Leu 275	GAA Glu	GAT Asp	CAA Gln	CTT Leu	AAA Lys 280	GCT Ala	GCT Ala	GAA Glu	GAA Glu	AAC Asn 285	AAT Asn	AAT Asn	984
40	GTA Val	GAA Glu	GAC Asp	TAC Tyr 290	TTT Phe	AAA Lys	GAA Glu	GGT Gly	TTA Leu 295	GAG Glu	AAA Lys	ACT Thr	ATT Ile	GCT Ala 300	GCT Ala	AAA Lys	1032
45	AAA Lys	GCT Ala	GAA Glu 305	TTA Leu	GAA Glu	AAA Lys	ACT Thr	GAA Glu 310	GCT Ala	GAC Asp	CTT Leu	AAG Lys	AAA Lys 315	GCA Ala	GTT Val	AAT Asn	1080
	GAG Glu 320	CCA Pro	GAA Glu	AAA Lys	CCA Pro	GCT Ala	CCA Pro	GCT Ala	CCA Pro	GAA Glu	ACT Thr	CCA Pro	GCC Ala	CCA Pro	GAA Glu	GCA Ala	1128



5	CCA Pro 335	GCT Ala	GAA Glu	CAA Gln	CCA Pro	AAA Lys 340	CCA Pro	GCG Ala	CCG Pro	GCT Ala	CCT Pro 345	CAA Gln	CCA Pro	GCT Ala	CCC Pro 350	GCA Ala	1176
	CCA Pro	AAA Lys	CCA Pro	GAG Glu 355	AAG Lys 355	CCA Pro	GCT Ala	GAA Glu	CAA Gln	CCA Pro 360	AAA Lys	CCA Pro	GAA Glu	AAA Lys	ACA Thr 365	GAT Asp	1224
10	GAT Asp	CAA Gln	CAA Gln	GCT Ala 370	GAA Glu	GAA Glu	GAC Asp	TAT Tyr	GCT Pro 375	CGT Arg	AGA Arg	TCA Ser	GAA Glu	GAA Glu	GAA Glu	TAT Tyr	1272
	AAT Asn	CGC Arg	TTG Leu 385	ACT Thr	CAA Gln	CAG Gln	CAA Gln	CCG Pro 390	CCA Pro	AAA Lys	GCT Ala	GAA Glu	AAA Lys 395	CCA Pro	GCT Ala	CCT Pro	1320
15	GCA Ala 400	CCA Pro	AAA Lys	ACA Thr	GGC Gly	TGG Trp	AAA Lys 405	CAA Gln	GAA Glu	AAC Asn	GGT Gly	ATG Met 410	TGG Trp	TAC Tyr	TTC Phe	TAC Tyr	1368
20	AAT Asn 415	ACT Thr	GAT Asp	GGT Gly	TCA Ser	ATG Met 420	GCG Ala	ACA Thr	GGA Gly	TGG Trp	CTC Leu 425	CAA Gln	AAC Asn	AAC Asn	GGT Gly	TCA Ser 430	1416
	TGG Trp	TAC Tyr	TAC Tyr	CTC Leu	AAC Asn 435	AGC Ser	AAT Asn	GGT Gly	GCT Ala	ATG Met 440	GCT Ala	ACA Thr	GGT Gly	TGG Trp	CTC Leu 445	CAA Gln	1464
25	TAC Tyr	AAT Asn	GGT Gly	TCA Ser 450	TGG Trp	TAT Tyr	TAC Tyr	CTC Leu	AAC Asn 455	GCT Ala	AAC Asn	GGC Gly	GCT Ala	ATG Met 460	GCA Ala	ACA Thr	1512
	GGT Gly	TGG Trp	GCT Ala 465	AAA Lys	GTC Val	AAC Asn	GGT Gly	TCA Ser 470	TGG Trp	TAC Tyr	TAC Tyr	CTC Leu	AAC Asn 475	GCT Ala	AAT Asn	GGT Gly	1560
30	GCT Ala 480	ATG Met	GCT Ala	ACA Thr	GGT Gly	TGG Trp	CTC Leu 485	CAA Gln	TAC Tyr	AAC Asn	GGT Gly	TCA Ser 490	TGG Trp	TAT Tyr	TAC Tyr	CTC Leu	1608
35	AAC Asn 495	GCT Ala	AAC Asn	GGC Gly	GCT Ala	ATG Met 500	GCA Ala	ACA Thr	GGT Gly	TGG Trp	GCT Ala 505	AAA Lys	GTC Val	AAC Asn	GGT Gly	TCA Ser 510	1656
	TGG Trp	TAC Tyr	TAC Tyr	CTC Leu	AAC Asn 515	GCT Ala	AAT Asn	GGT Gly	GCT Ala	ATG Met 520	GCT Ala	ACA Thr	GGT Gly	TGG Trp	CTC Leu 525	CAA Gln	1704
40	TAC Tyr	AAC Asn	GGT Gly	TCA Ser 530	TGG Trp	TAC Tyr	TAC Tyr	CTC Leu	AAC Asn 535	GCT Ala	AAC Asn	GGT Gly	GCT Ala	ATG Met 540	GCT Ala	ACA Thr	1752
	GGT Gly	TGG Trp	GCT Ala 545	AAA Lys	GTC Val	AAC Asn	GGT Gly	TCA Ser 550	TGG Trp	TAC Tyr	TAC Tyr	CTC Leu	AAC Asn 555	GCT Ala	AAT Asn	GGT Gly	1800
45	GCT Ala 560	ATG Met	GCA Ala	ACA Thr	GGT Gly	TGG Trp	GTG Val 565	AAA Lys	GAT Asp	GGA Gly	GAT Asp	ACC Thr	TGG Trp	TAC Tyr	TAT Tyr	CTT Leu	1848

50

55

5 GAA GCA TCA GGT GCT ATG AAA GCA AGC CAA TGG TTC AAA GTA TCA GAT 1896  
 Glu Ala Ser Gly Ala Met Lys Ala Ser Gln Trp Phe Lys Val Ser Asp 590  
 575 580 585

AAA TGG TAC TAT GTC AAT GGT TTA GGT GCC CTT GCA GTC AAC ACA ACT 1944  
 Lys Trp Tyr Tyr Val Asn Gly Leu Gly Ala Leu Ala Val Asn Thr Thr 605  
 595 600

10 GTA GAT GGC TAT AAA GTC AAT GCC AAT GGT GAA TGG GTT TAA GCC GAT 1992  
 Val Asp Gly Tyr Lys Val Asn Ala Asn Gly Glu Trp Val \* 610 615

TAA ATT AAA GCA TGT TAA GAA CAT TTG ACA TTT TAA TTT TGA AAC AAA 2040

15 GAT AAG GTT CGA TTG AAT AGA TTT ATG TTC GTA TTC TTT AGG TAC 2085

## (2) INFORMATION FOR SEQ ID NO:2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 619 amino acids  
 (B) TYPE: amino acid  
 (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Asn Lys Lys Lys Met Ile Leu Thr Ser Leu Ala Ser Val Ala Ile  
 1 5 10 15

Leu Gly Ala Gly Phe Val Ala Ser Gln Pro Thr Val Val Arg Ala Glu  
 20 25 30

Glu Ser Pro Val Ala Ser Gln Ser Lys Ala Glu Lys Asp Tyr Asp Ala  
 35 40 45

Ala Lys Lys Asp Ala Lys Asn Ala Lys Lys Ala Val Glu Asp Ala Gln  
 50 55 60

Lys Ala Leu Asp Asp Ala Lys Ala Ala Gln Lys Lys Tyr Asp Glu Asp  
 65 70 75 80

Gln Lys Lys Thr Glu Glu Lys Ala Ala Leu Glu Lys Ala Ala Ser Glu  
 85 90 95

Glu Met Asp Lys Ala Val Ala Ala Val Gln Gln Ala Tyr Leu Ala Tyr  
 100 105 110

Gln Gln Ala Thr Asp Lys Ala Ala Lys Asp Ala Ala Asp Lys Met Ile  
 115 120 125

Asp Glu Ala Lys Lys Arg Glu Glu Glu Ala Lys Thr Lys Phe Asn Thr  
 130 135 140

Val Arg Ala Met Val Val Pro Glu Pro Glu Gln Leu Ala Glu Thr Lys  
 145 150 155 160

Lys Lys Ser Glu Glu Ala Lys Gln Lys Ala Pro Glu Leu Thr Lys Lys  
 165 170 175  
 5 Leu Glu Glu Ala Lys Ala Lys Leu Glu Glu Ala Glu Lys Lys Ala Thr  
 180 185 190  
 Glu Ala Lys Gln Lys Val Asp Ala Glu Glu Val Ala Pro Gln Ala Lys  
 195 200 205  
 10 Ile Ala Glu Leu Glu Asn Gln Val His Arg Leu Glu Gln Glu Leu Lys  
 210 215 220  
 Glu Ile Asp Glu Ser Glu Ser Glu Asp Tyr Ala Lys Glu Gly Phe Arg  
 225 230 235 240  
 15 Ala Pro Leu Gln Ser Lys Leu Asp Ala Lys Lys Ala Lys Leu Ser Lys  
 245 250 255  
 Leu Glu Glu Leu Ser Asp Lys Ile Asp Glu Leu Asp Ala Glu Ile Ala  
 260 265 270  
 20 Lys Leu Glu Asp Gln Leu Lys Ala Ala Glu Glu Asn Asn Asn Val Glu  
 275 280 285  
 Asp Tyr Phe Lys Glu Gly Leu Glu Lys Thr Ile Ala Ala Lys Lys Ala  
 290 295 300  
 25 Glu Leu Glu Lys Thr Glu Ala Asp Leu Lys Lys Ala Val Asn Glu Pro  
 305 310 315 320  
 Glu Lys Pro Ala Pro Ala Pro Glu Thr Pro Ala Pro Glu Ala Pro Ala  
 325 330 335  
 30 Glu Gln Pro Lys Pro Ala Pro Ala Pro Gln Pro Ala Pro Ala Pro Lys  
 340 345 350  
 Pro Glu Lys Pro Ala Glu Gln Pro Lys Pro Glu Lys Thr Asp Asp Gln  
 355 360 365  
 35 Gln Ala Glu Glu Asp Tyr Ala Arg Arg Ser Glu Glu Glu Tyr Asn Arg  
 370 375 380  
 Leu Thr Gln Gln Gln Pro Pro Lys Ala Glu Lys Pro Ala Pro Ala Pro  
 385 390 395 400  
 40 Lys Thr Gly Trp Lys Gln Glu Asn Gly Met Trp Tyr Phe Tyr Asn Thr  
 405 410 415  
 Asp Gly Ser Met Ala Thr Gly Trp Leu Gln Asn Asn Gly Ser Trp Tyr  
 420 425 430  
 45 Tyr Leu Asn Ser Asn Gly Ala Met Ala Thr Gly Trp Leu Gln Tyr Asn  
 435 440 445  
 Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ala Met Ala Thr Gly Trp  
 450 455 460  
 50 Ala Lys Val Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ala Met  
 465 470 475 480

Ala Thr Gly Trp Leu Gln Tyr Asn Gly Ser Trp Tyr Tyr Leu Asn Ala  
 485 490 495

5 Asn Gly Ala Met Ala Thr Gly Trp Ala Lys Val Asn Gly Ser Trp Tyr  
 500 505 510

Tyr Leu Asn Ala Asn Gly Ala Met Ala Thr Gly Trp Leu Gln Tyr Asn  
 515 520 525

10 Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ala Met Ala Thr Gly Trp  
 530 535 540

Ala Lys Val Asn Gly Ser Trp Tyr Tyr Leu Asn Ala Asn Gly Ala Met  
 545 550 555 560

15 Ala Thr Gly Trp Val Lys Asp Gly Asp Thr Trp Tyr Tyr Leu Glu Ala  
 565 570 575

Ser Gly Ala Met Lys Ala Ser Gln Trp Phe Lys Val Ser Asp Lys Trp  
 580 585 590

20 Tyr Tyr Val Asn Gly Leu Gly Ala Leu Ala Val Asn Thr Thr Val Asp  
 595 600 605

Gly Tyr Lys Val Asn Ala Asn Gly Glu Trp Val  
 610 615

(3) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 33 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

GCGCGTCGAC GGCTTAAACC CATTACCAT TGG

33

(4) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:  
 (A) LENGTH: 28 base pairs  
 (B) TYPE: nucleic acid  
 (C) STRANDEDNESS: single  
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

CCGGATCCTG AGCCAGAGCA GTTGGCTG

28

## (5) INFORMATION FOR SEQ ID NO:5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

## (ii) MOLECULE TYPE: DNA (genomic)

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCGGATCCGC TCAAAGAGAT TGATGAGTCT G

31

## Claims

1. An isolated pneumococcal surface protein A (PspA) protein fragment comprising amino acid residues corresponding to all or some of amino acid residues 192 to 260 of the PspA protein of the Rx1 strain of Streptococcus pneumoniae containing at least one protection-eliciting epitope and optionally up to a further 25 residues of said protein in the NH<sub>2</sub> terminal direction and/or the COOH terminal direction, or being effectively homologous with such a protein fragment.
2. A protein fragment as claimed in Claim 1, containing an amino acid sequence corresponding to amino acid residues 192 to 260 of the PspA protein of the Rx1 strain.
3. A protein fragment as claimed in Claim 2, having said amino acid sequence.
4. A protein fragment as claimed in Claim 1, 2 or 3 containing an amino acid sequence effectively homologous to the amino acid residues 192 to 260 of the PspA protein of said Rx1 strain.
5. A protein fragment as claimed in Claim 4, constituted by an amino acid sequence effectively homologous to the amino acid residues 192 to 260 of the PspA protein of said Rx1 strain.
6. A protein fragment claimed in any one of Claims 1 to 5 which is produced recombinantly.
7. An isolated protein fragment comprising the amino acid sequence of or effectively homologous with that of a protection-eliciting epitope corresponding to an epitope contained in amino acid residues 192 to 260 of the pneumococcal surface protein A (PspA) protein of the Rx1 strain of Streptococcus pneumoniae, and including no more than 25 additional amino acid residues in the NH<sub>2</sub> and/or the COOH terminal direction.
8. A pneumococcal surface protein A (PspA) protein fragment comprising a plurality of conjugated molecules, each molecule comprising an isolated protein fragment corresponding to or effectively homologous with a protection-eliciting epitope corresponding to an epitope located in residues 192 to 260 of the PspA of strain Rx1 molecules within said plurality optionally being derived from different strains of S. pneumoniae.
9. A vaccine against disease caused by pneumococcal infection, comprising, as an immunologically-active component, a PspA protein fragment as claimed in any one of Claims 1 to 8.
10. A vaccine as claimed in Claim 9, characterised in that said PspA protein fragment is as claimed in any one of Claims 1 to 7 and is conjugated to a large molecule.
11. A DNA primer or probe having the nucleotide sequence:-

5' - CCGGATCCTGAGCCAGAGCAGTTGGCTG - 3'

12. A DNA primer or probe having the nucleotide sequence:-

5' - CCGGATCCGCTCAAAGAGATTGATGAGTCTG - 3'

5

10

15

20

25

30

35

40

45

50

55

FIG. 18.

peps - sequence -> 1-phase Translation		DNA and derived amino acid 2085 b.p. AAGCTTATGATA.....TCCTTAGGTACC linear	
		31 / II	
AAG CCT ATG ATA TAG AAA TTT GTA ACA AAA ATG TAA TAT AAA ACA CTT GAC AAA TAT TTA			
61 / 21		91 / 31	
CGG AAG AAG CTT ATA CTT AAT ATA AGT ATA GTC TGA AAA TGA CTA TCA GAA AAG AAG TAA			
121 / 41		151 / 51	
ATT TAG ATG AAT AAG AAA AAA ATG ATT TTA ACA AGT CTA GCC AAG GTC GCT ATC TTA GGG			
181 / 61		211 / 71	
GCT GGT TTT GTT GCG TCT CAG CCT ACT GTT GTA AGA GCA GAA GAA TCT CCC GTC GCC AGT			
241 / 81		271 / 91	
CAG TCT AAA GCT GAG AAA GAC TAT GAT GCA GCG AAG AAA GAT GCT AAG AAT GCG AAA AAA			
301 / 101		331 / 111	
GCA GTA GAA GAT GCT CAA AAG GCT TTA GAT GAT GCA AAA GCT GCT CAG AAA AAA TAT GAC			
361 / 121		391 / 131	
GAG GAT CAG AAG AAA ACT GAG GAG AAA GCC GCG CTA GAA AAA GCA GCG TCT GAA GAG ATG			
421 / 141		451 / 151	
GAT AAG GCA GTG GCA GCA GTT CAA CAA GCG TAT CTA GCC TAT CAA CAA GCT ACA CAC AAA			
481 / 161		511 / 171	
GCC GCA AAA GAC GCA GCA GAT AAG ATG ATA GAT GAA GCT AAG AAA CCG GAA GAG GCA			
541 / 181		571 / 191	
AAA ACT AAA TTT AAT ACT GTT CCA GCA ATG GCA ATG GTA GTT CCT GAG CAG TTG GCT GAG			
601 / 201		631 / 211	
ACT AAG AAA AAA TCA GAA GAA GCT AAA CAA AAA GCA CCA GAA CTT ACT AAA AAA CTA GAA			
thr	lys	lys	thr

FIG.1b.

661	/	221	GCA	AAA	TTA	GAA	GAG	GCT	GAG	AAA	691	/	231	ACT	GAA	GCC	AAA	CAA	AAA	GTG
glu	lys	lys	ala	lys	leu	glu	glu	ala	glu	lys	lys	lys	ala	thr	glu	ala	lys	gln	lys	val
721	/	241	GAT	GAA	GCT	CCT	CAA	GCT	AAA	ATC	751	/	251	TTG	GAA	AAT	CAA	GTT	CAT	AGA
asp	ala	glu	glu	val	ala	pro	gln	ala	lys	ile	ile	ala	glu	leu	glu	asn	gln	val	his	arg
781	/	261	CTA	GAA	CAA	GAG	CTC	AAA	GAG	ATT	811	/	271	GAA	CAT	TAT	GCT	AAA	GAA	GGT
leu	glu	gln	glu	leu	lys	glu	leu	asp	glu	ile	ser	glu	ser	glu	asp	tyr	ala	lys	glu	gly
841	/	281	TTC	GCT	CCT	CAA	TCT	AAA	TTG	GAT	871	/	291	GCT	AAA	CTA	TCA	AAA	CTT	GAA
phe	arg	ala	pro	leu	leu	gln	ser	lys	leu	asp	ala	lys	lys	ala	lys	leu	ser	lys	leu	glu
901	/	301	CAG	TTA	AGT	GAT	AAG	ATT	GAT	GAG	931	/	311	GCA	AAA	CTT	GAA	GAT	CAA	CTT
glu	leu	ser	asp	lys	ile	asp	lys	asp	glu	leu	ala	glu	ile	ala	lys	leu	glu	asp	gln	leu
961	/	321	AAA	GCT	GCT	GAA	GAA	AAC	AAT	GTA	991	/	331	AAA	GAA	GGT	TTA	GAG	AAA	ACT
lys	ala	ala	glu	glu	ala	asn	asn	asn	val	glu	asp	thr	phe	lys	glu	gly	leu	glu	lys	thr
1021	/	341	ATT	GCT	GCT	AAA	GCT	GAA	TTA	GAA	1051	/	351	GAC	CTT	AAG	AAA	GCA	GTT	AAT
ile	ala	ala	lys	lys	ala	glu	ala	glu	leu	lys	thr	glu	thr	asp	leu	lys	lys	ala	val	asn
1081	/	361	GAG	CCA	GAA	AAA	CCA	GCT	CCA	GCT	1111	/	371	CCA	GAA	CCA	CCA	GCT	GAA	CAA
glu	pro	glu	lys	pro	ala	ala	pro	ala	pro	glu	thr	pro	ala	pro	glu	ala	pro	ala	glu	gln
1141	/	381	CCA	AAA	CCA	GCG	CCG	GCT	CAA	CCA	1171	/	391	AAA	CCA	GAG	AAG	CCA	GCT	GAA
pro	lys	pro	ala	pro	ala	pro	pro	pro	gln	pro	pro	ala	pro	lys	pro	glu	lys	pro	ala	glu
1201	/	401	CAA	CCA	AAA	CCA	CAA	AAA	ACA	GAT	1231	/	411	GAA	GAC	TAT	GCT	CGT	AGA	TCA
gln	pro	lys	pro	glu	lys	thr	thr	thr	asp	asp	gln	ala	GLU	gln	asp	tyr	ala	arg	arg	ser
1261	/	421	GAA	GAA	GAA	TAT	AAT	GGC	TTG	ACT	1291	/	431	AAA	CTT	CAA	AAA	CCA	GCT	CCT
glu	glu	glu	tyr	asn	arg	leu	thr	leu	thr	gln	gln	pro	pro	lys	ala	glu	lys	pro	ala	pro
1321	/	441	GCA	CCA	CCA	TGG	AAA	TGG	AAA	CAA	1351	/	451	TAC	TTC	TAC	AAT	ACT	GAT	GGT
ala	pro	lys	thr	gly	trp	lys	gln	gln	glu	asn	gly	met	trp	tyr	phe	tyr	asn	thr	asp	gly



1381	/	461	ACA	GGT	GGG	CTC	CAA	AAC	AAC	GGT	1411	/	471	TAC	TAC	CTC	AAC	AGC	AAT	GGT
TCA	ATG	GCG	thr	gly	trp	leu	gln	asn	asn	gly	1471	/	TGG	tyr	tyr	leu	asn	ser	asn	gly
ser	met	ala	thr	gly	trp	leu	gln	asn	asn	gly	1531	/	TGG	TAT	TAC	CTC	AAC	GCT	AAC	GGC
1441	/	481	ACA	GGT	GGG	CTC	CAA	TAC	AAT	GGT	1591	/	TGG	tyr	tyr	leu	asn	ala	asn	gly
GCT	ATG	GCT	thr	gly	trp	leu	gln	asn	asn	gly	1651	/	TGG	TAT	TAC	CTC	AAC	GCT	AAT	GGT
ala	met	ala	thr	gly	trp	leu	gln	asn	asn	gly	1711	/	TGG	TAT	TAC	CTC	AAC	GCT	AAT	GGT
1501	/	501	ACA	GGT	GGG	GCT	AAA	GTC	AAC	GGT	1771	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
GCT	ATG	GCA	thr	gly	trp	ala	lys	val	asn	gly	1831	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
ala	met	ala	thr	gly	trp	ala	lys	val	asn	gly	1891	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
1561	/	521	ACA	GGT	GGG	GCT	AAA	GTC	AAC	GGT	1951	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
GCT	ATG	GCT	thr	gly	trp	leu	gln	asn	asn	gly	2011	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
ala	met	ala	thr	gly	trp	leu	gln	asn	asn	gly	2071	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
1621	/	541	ACA	GGT	GGG	GCT	CAA	TAC	AAC	GGT	2131	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
GCT	ATG	GCA	thr	gly	trp	leu	gln	asn	asn	gly	2191	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
ala	met	ala	thr	gly	trp	ala	lys	val	asn	gly	2251	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
1681	/	561	ACA	GGT	GGG	GCT	AAA	GTC	AAC	GGT	2311	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
GCT	ATG	GCT	thr	gly	trp	leu	gln	asn	asn	gly	2371	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
ala	met	ala	thr	gly	trp	leu	gln	asn	asn	gly	2431	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
1741	/	581	ACA	GGT	GGG	GCT	CAA	TAC	AAC	GGT	2491	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
GCT	ATG	GCT	thr	gly	trp	leu	gln	asn	asn	gly	2551	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
ala	met	ala	thr	gly	trp	ala	lys	val	asn	gly	2611	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
1801	/	601	ACA	GGT	GGG	GCT	AAA	GTC	AAC	GGT	2671	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
GCT	ATG	GCA	thr	gly	trp	leu	gln	asn	asn	gly	2731	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
ala	met	ala	thr	gly	trp	ala	lys	val	asn	gly	2791	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
1861	/	621	ACA	GGT	GGG	GCT	AAA	GTC	AAC	GGT	2851	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
GCT	ATG	GCA	thr	gly	trp	leu	gln	asn	asn	gly	2911	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
ala	met	ala	thr	gly	trp	ala	lys	val	asn	gly	2971	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
1921	/	641	ACA	GGT	GGG	GCT	AAA	GTC	AAC	GGT	3031	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	GGT
GCT	ATG	AAA	thr	gly	trp	leu	gln	asn	asn	gly	3091	/	TGG	TAC	TAC	CTC	AAC	GCT	AAT	




FIG.2.




FIG.3.




FIG.4.

pKSD1014

pIN

pJY4306

pJY4310

pJY4285

pBC100

pBC207



Europäisches Patentamt

European Patent Office

Office européen des brevets



Publication number : **0 622 081 A3**

(12)

## EUROPEAN PATENT APPLICATION

(21) Application number : **94302767.2**

(51) Int. Cl.<sup>5</sup> : **A61K 39/09, C07K 13/00,  
C12Q 1/68**

(22) Date of filing : **19.04.94**

(30) Priority : **20.04.93 US 48896**

(43) Date of publication of application :  
**02.11.94 Bulletin 94/44**

(84) Designated Contracting States :  
**AT BE CH DE DK ES FR GB GR IE IT LJ LU MC  
NL PT SE**

(88) Date of deferred publication of search report :  
**15.11.95 Bulletin 95/46**

(71) Applicant : **UAB RESEARCH FOUNDATION  
P.O. Box 1000  
Birmingham Alabama 35294 (US)**

(72) Inventor : **Briles, David E.  
760 Linwood Road  
Birmingham, Alabama 35222 (US)  
Inventor : Yother, Janet L.  
2208 Heatherbrooke Road  
Birmingham, Alabama 35242 (US)  
Inventor : McDaniel, Larry S.  
5354 Cornell Drive  
Birmingham, Alabama 35210 (US)**

(74) Representative : **Smart, Peter John  
W.H. BECK, GREENER & CO  
7 Stone Buildings  
Lincoln's Inn  
London WC2A 3SZ (GB)**

(54) **Epitopic regions of pneumococcal surface protein A.**

(57) A region of the PspA protein of the Rxl strain of protection-eliciting epitopes which are cross-reactive with PspAs of other *S. pneumoniae* strains. The region comprises the 68 amino acid sequence extending from amino acid residues 192 to 260 of the Rx1 PspA strain.

EP 0 622 081 A3



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 94 30 2767

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. CL.5)
1 X, D	WO-A-92 14488 (UAB RESEARCH FOUNDATION) 1992 * page 8, line 3 - page 14, line 10 * * example 9 * * example 10 * * figure 5 *	1-7, 9, 10	A61K39/09 C07K13/00 C12Q1/68
Y	---	8	
7 X	ABSTRACTS OF THE 92ND GENERAL MEETING OF THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 0, 1992 page 70 BRILES D.E. ET AL 'Mapping protection eliciting epitopes of pneumococcal surface protein A (PspA)' *abstract B-268*	1-7, 9, 10	
6 X	MICROBIAL PATHOGENESIS, vol. 13, 1992 ABERDEEN, GB, pages 261-269, MCDANIEL L.S. ET AL 'Molecular localization of variable and conserved regions of PspA and identification of additional PspA homologous sequences in Streptococcus pneumoniae' * the whole document *	11, 12	TECHNICAL FIELDS SEARCHED (Int. CL.5) C07K C12Q
6 X	INFECTION AND IMMUNITY, vol. 59, no. 4, 1991 WASHINGTON US, pages 1285-1289, TALKINGTON D. ET AL 'A 43-kilodalton Pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence' * the whole document *	1-7, 9, 10	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 18 September 1995	Examiner Fernandez y Branas, F
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons A : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EP FORM 150 (04/92) (PVC)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 94 30 2767

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
7 T	MICROBIAL PATHOGENESIS, vol. 17, November 1994 ABERDEEN GB, pages 323-337, MCDANIEL L.S. ET AL 'Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260' * the whole document *	1-12	
7 X	JOURNAL OF BACTERIOLOGY, vol. 174, no. 2, BALTIMORE, pages 601-609, YOTHER, J. ET AL 'Structural properties and evolutionary relationships of PspA, a surface protein of Streptococcus pneumoniae, as revealed by sequence analysis' * the whole document *	1,2,4-7	
7 Y	THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 163, no. 6, 1986 NEW YORK, pages 1451-1458, BEACHEY E.H. ET AL 'Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem' * the whole document *	8	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl.5)
Place of search THE HAGUE		Date of completion of the search 18 September 1995	Examiner Fernandez y Branas, F
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- A : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1500 (01.92) (P4/C)

**THIS PAGE BLANK (USPTO)**